The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
124432333 12443233 3 F 20080428 20160721 20160607 20160803 EXP CA-JNJFOC-20160421479 JANSSEN 31.05 YR A F Y 66.00000 KG 20160803 OT CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
124432333 12443233 1 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) 56 INFUSIONS TILL DATE Y U FKM95011;UNKNOWN;GAM08011;GBM13012 0 300 MG LYOPHILIZED POWDER
124432333 12443233 2 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) Y U FKM95011;UNKNOWN;GAM08011;GBM13012 0 LYOPHILIZED POWDER
124432333 12443233 3 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) Y U FKM95011;UNKNOWN;GAM08011;GBM13012 0 300 MG LYOPHILIZED POWDER
124432333 12443233 4 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) Y U FKM95011;UNKNOWN;GAM08011;GBM13012 0 300 MG LYOPHILIZED POWDER
124432333 12443233 5 SS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) Y U FKM95011;UNKNOWN;GAM08011;GBM13012 0 300 MG LYOPHILIZED POWDER
124432333 12443233 6 PS REMICADE INFLIXIMAB 1 Intravenous (not otherwise specified) Y U FKM95011;UNKNOWN;GAM08011;GBM13012 103772 300 MG LYOPHILIZED POWDER
124432333 12443233 7 C CITALOPRAM CITALOPRAM HYDROBROMIDE 1 Unknown 0 UNSPECIFIED
124432333 12443233 8 C IMODIUM LOPERAMIDE HYDROCHLORIDE 1 Unknown 0 UNSPECIFIED
124432333 12443233 9 C BUSCOPAN BUTYLSCOPOLAMINE BROMIDE 1 Unknown 0 UNSPECIFIED
124432333 12443233 10 C T4 LEVOTHYROXINE 1 Unknown 0 UNSPECIFIED
124432333 12443233 11 C VITAMIN D CHOLECALCIFEROL 1 Unknown 0 2000 IU UNSPECIFIED QD
124432333 12443233 12 C MAGNESIUM MAGNESIUM 1 Unknown 0 UNSPECIFIED

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
124432333 12443233 1 Colitis ulcerative
124432333 12443233 2 Colitis ulcerative
124432333 12443233 3 Colitis ulcerative
124432333 12443233 4 Colitis ulcerative
124432333 12443233 5 Colitis ulcerative
124432333 12443233 6 Colitis ulcerative

Outcome of event

Event ID CASEID OUTC COD
124432333 12443233 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
124432333 12443233 Abdominal pain
124432333 12443233 Anorectal disorder
124432333 12443233 Dizziness
124432333 12443233 Fatigue
124432333 12443233 Feeling abnormal
124432333 12443233 Frequent bowel movements
124432333 12443233 General physical health deterioration
124432333 12443233 Haematochezia
124432333 12443233 Herpes zoster
124432333 12443233 Mucous stools
124432333 12443233 Off label use
124432333 12443233 Paraesthesia
124432333 12443233 Product use issue

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
124432333 12443233 2 20160421 0
124432333 12443233 3 20070418 0
124432333 12443233 4 20080428 0
124432333 12443233 5 20160602 0
124432333 12443233 6 20160721 0